Researcher profile · Semantic Scholar

Fernanda I. Arnaldez

h-index: 12
Works: 34
Citations: 809

Most-cited papers

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
C. Aggarwal, A. Prawira, S. Antonia, O. Rahma +25 more
2022Journal for ImmunoTherapy of Cancer141 citations Open access
Semantic Scholar
Role of Fcγ receptors in HER2-targeted breast cancer therapy
A. Musolino, W. Gradishar, H. Rugo, J. Nordstrom +3 more
2022Journal for ImmunoTherapy of Cancer110 citations Open access
Semantic Scholar
Targeting the Insulin Growth Factor Receptor 1
Fernanda I. Arnaldez, L. Helman
2012Hematology/Oncology Clinics of North America92 citations Open access
Semantic Scholar
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
Fernanda I. Arnaldez, O, S. J. Day, C. Drake +8 more
2020Journal for ImmunoTherapy of Cancer89 citations Open access
Semantic Scholar
A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript
Patrick J. Grohar, J. Glod, C. Peer, T. Sissung +6 more
2017Cancer Chemotherapy and Pharmacology67 citations Open access
Semantic Scholar
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group
A. Magnuson, S. Bruinooge, H. Singh, K. Wilner +13 more
2021Clinical Cancer Research64 citations Open access
Semantic Scholar
Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma
C. Heske, Mindy I. Davis, J. Baumgart, Kelli M. Wilson +14 more
2017Clinical Cancer Research57 citations Open access
Semantic Scholar
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth
C. Yeung, Vu N. Ngo, Patrick J. Grohar, Fernanda I. Arnaldez +7 more
2013Oncogene44 citations Open access
Semantic Scholar
New Strategies in Ewings Sarcoma: Lost in Translation?
Fernanda I. Arnaldez, L. Helman
2014Clinical Cancer Research30 citations Open access
Semantic Scholar
Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond
F. Comer, Y. Mazor, Elaine M. Hurt, Chun-Ning Yang +15 more
2023Cancer Research26 citations
Semantic Scholar
Safety and efficacy of catheter directed thrombolysis in children with deep venous thrombosis
Deepika S. Darbari, D. Desai, Fernanda I. Arnaldez, K. Desai +5 more
2012British Journal of Haematology15 citations
Semantic Scholar
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-associated Renal Cell Carcinoma
John A. Ligon, R. Sundby, Mary F. Wedekind Malone, Fernanda I. Arnaldez +28 more
2022Clinical Cancer Research13 citations Open access
Semantic Scholar
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.
C. Aggarwal, C. Azzoli, A. Spira, B. Solomon +16 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
A. Clark, F. Hong, R. Finn, A. DeMichele +19 more
2023Clinical Cancer Research11 citations Open access
Semantic Scholar
Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate
L. McGrath, Ying Zheng, Simon Christ, C. Sachs +12 more
2023Cancer Research9 citations
Semantic Scholar
A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer.
J. del Rivero, Fernanda I. Arnaldez, R. Srinivasan, Melissa Spencer +8 more
20185 citations
Semantic Scholar
The Liddy Shriver Sarcoma Initiative
Fernanda I. Arnaldez, D. Loeb
20115 citations
Semantic Scholar
A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.
M. Wedekind, J. del Rivero, Fernanda I. Arnaldez, R. Srinivasan +9 more
20204 citations
Semantic Scholar
Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors
A. Clark, F. Hong, R. Finn, A. DeMichele +19 more
2019Clinical research4 citations
Semantic Scholar
Drivers of Clinical Trial Participation-Demographics, Disparities, and Eligibility Criteria.
G. Mishkin, Fernanda I. Arnaldez, S. P. Ivy
2019JAMA Oncology4 citations
Semantic Scholar
A phase II trial of vandetanib (ZD6474) in children and adults with wild-type gastrointestinal stromal tumors.
J. Glod, Fernanda I. Arnaldez, L. Wiener, Melissa Amaya +7 more
20164 citations
Semantic Scholar
Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.
K. Do, J. Hays, Stephen V. Liu, Alice P. Chen +15 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar
Update on antibody–drug conjugates: where are we now, & where are we going?
Fernanda I. Arnaldez
2022Immuno Oncology Insights0 citations
Semantic Scholar
Cancer Immunotherapy 2020: Opportunities and Challenges on the Road Ahead
Fernanda I. Arnaldez, J. Wigginton
20200 citations
Semantic Scholar
SUN-341 A Natural History Study for Rare Tumors: An Avenue for Discovering and Understanding Endocrine Cancers
B. Thomas, Sarah Fuller, Maran Ilanchezhian, Deborah H. Allen +11 more
2019Journal of the Endocrine Society0 citations Open access
Semantic Scholar
Clinical characterization of patients with SDHC epimutation in gastrointestinal stromal tumors.
Maran Ilanchezhian, Sarah Fuller, M. Raygada, C. Stratakis +5 more
2019Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract A46: HSP-90 inhibition in pediatric sarcomas
Fernanda I. Arnaldez, T. Terwilliger, C. Yeung, L. Neckers +1 more
20140 citations
Semantic Scholar
Abstract IA33: Combination targeted therapy in pediatric sarcomas
L. Helman, Fernanda I. Arnaldez, C. Heske, X. Wan +1 more
20140 citations
Semantic Scholar
Heat-shock protein 90 inhibition in pediatric sarcomas.
Fernanda I. Arnaldez, E. Gombos, T. Terwilliger, A. Mendoza +3 more
20140 citations
Semantic Scholar
New Strategies in Ewing ’ s Sarcoma : Lost in Translation ? Running title : New Strategies in Ewing ’ s Sarcoma
Fernanda I. Arnaldez, L. Helman
20140 citations
Semantic Scholar
Integrated analysis of RNAi screens in pediatric rhabdomyosarcoma.
Fernanda I. Arnaldez, S. Chakka, Carly J. Smith, C. Yeung +2 more
20130 citations
Semantic Scholar
Identification of TNK2 as a critical kinase in rhabdomyosarcoma through a loss of function shRNA screen.
Fernanda I. Arnaldez, C. Yeung, Carly J. Smith, N. Caplen +1 more
20120 citations
Semantic Scholar
Abstract 5348: In vivo and in vitro alveolar rhabdomyosarcoma cell growth is affected by TNK2 expression
Fernanda I. Arnaldez, C. Yeung, L. Helman
20110 citations
Semantic Scholar
Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth.
Fernanda I. Arnaldez, C. Yeung, Patrick J. Grohar, L. Helman
20100 citations
Semantic Scholar

J. del Rivero

×4

R. Srinivasan×4

S. Steinberg×4

W. Linehan×4

P. Meltzer×4

Patrick J. Grohar×3

C. Peer×3

L. McGrath×3